Allergy Asthma Proc:哮喘和鼻炎控制对工作效率和活动障碍的交互影响

2021-07-24 AlexYang MedSci原创

有症状的哮喘和鼻炎对患者的工作效率和活动有负面影响。然而,人们对哮喘和鼻炎控制对工作效率和活动障碍的潜在交互影响知之甚少。

有症状的哮喘和鼻炎对患者的工作效率和活动有负面影响。然而,人们对哮喘和鼻炎控制对工作效率和活动障碍的潜在交互影响知之甚少。

近期,有研究人员探索了哮喘和鼻炎的控制对哮喘和鼻炎患者的工作效率和活动障碍是否存在交互作用

研究人员共前瞻性地招募了206名成年患者,根据哮喘和鼻炎的症状控制状况分为四组:均控制不佳(BPC)(n=53),哮喘控制不佳(PCA)与鼻炎控制良好(CR)(n=38),哮喘控制良好与鼻炎控制不佳(n=43),以及均控制良好(BWC)(n=72)。劳动生产率下降和活动障碍、哮喘控制和鼻炎控制分别用劳动生产率和活动障碍调查表评估,内容包括一般健康、哮喘控制测试和鼻炎控制评估测试。还采用一般线性回归模型来研究哮喘控制、鼻炎控制以及相互作用对工作效率和活动障碍的贡献。

结果发现,在BPC组的患者中,工作生产力的损失是最常见的。与BWC组的患者相比,PCA-CR组的患者活动障碍明显较高,与哮喘相关的生活质量较差(均为P<0.001)。哮喘和鼻炎控制有明显的交互作用,这也是造成缺勤率增加、工作效率下降和活动障碍增加的原因(所有的P<0.001)。尽管各组间的缺勤率差异不大,但控制水平对缺勤率有显著的交互作用(P=0.035)。

综上所述,哮喘和鼻炎控制的不同交互作用反映了上呼吸道和下呼吸道之间的联系,表明在哮喘管理中不能忽视鼻炎控制以及哮喘和鼻炎控制的交互作用

原始出处:

Wen Juan Zhu, Ying Liu, Gang Wang et al. Interaction effects of asthma and rhinitis control on work productivity and activity impairment: A cross-sectional study. Allergy Asthma Proc. Jul 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2022-02-16 linlin2312
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2022-06-15 skhzy
  6. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-26 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-26 sunylz
  8. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 @gxl

    非常受用

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 @gxl

    非常受用

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2006909, encodeId=556c20069095a, content=<a href='/topic/show?id=1be46519e1c' target=_blank style='color:#2F92EE;'>#活动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65197, encryptionId=1be46519e1c, topicName=活动障碍)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Fri Apr 29 05:48:07 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712870, encodeId=ed011e12870a9, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Apr 13 07:48:07 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650959, encodeId=22d5165095940, content=<a href='/topic/show?id=82d74e8850d' target=_blank style='color:#2F92EE;'>#工作效率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47885, encryptionId=82d74e8850d, topicName=工作效率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26da24104226, createdName=chenshujs, createdTime=Tue Jan 11 01:48:07 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977039, encodeId=55a819e70398c, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Feb 16 07:48:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977178, encodeId=547519e7178ea, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Wed Jun 15 08:48:07 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329532, encodeId=f4bd13295329c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602376, encodeId=66ba16023e61e, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jul 26 02:48:07 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002360, encodeId=906f100236002, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:23:04 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002356, encodeId=bd4c100235676, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:22:38 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002325, encodeId=f1de10023252a, content=非常受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210724/725901dc0ed249ebba9d096aacddde3f/a89b874e17434adb82b0c2dff5f374f1.jpg, createdBy=c0225555986, createdName=@gxl, createdTime=Sat Jul 24 19:01:16 CST 2021, time=2021-07-24, status=1, ipAttribution=)]
    2021-07-24 @gxl

    非常受用

    0

相关资讯

PLoS One:过敏性鼻炎稳定以及吸烟减少情况下年轻成年人的哮喘却在增加

在20世纪下半叶,哮喘和过敏性鼻炎(AR)的患病率在世界大部分地区都有增加,包括瑞典。然而,后来的研究对患病率的趋势呈现了不一致的结果。一些研究报告表明,以前哮喘的上升趋势已经达到了稳定,特别是在儿童

梅斯呼吸疾病进展(第007期)

往期参见:梅斯呼吸疾病进展(第006期)

Clin Exp Allergy:特应性皮炎合并哮喘的成人全因死亡增加

AD、哮喘或同时患有这两种疾病的成人死亡风险增加,与仅有哮喘相比,AD合并哮喘会增加患者死亡风险。

Lancet Respirat Med:Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响

Tezepelumab治疗可显著减少哮喘患者气道粘膜下的嗜酸性粒细胞

JAMA:3D vs 2D方案用于持续性中重度哮喘的治疗

对于持续性中重度哮喘患者,吸入皮质类固醇、长效β2激动剂以及长效M受体拮抗剂的3D治疗方案显著降低患者严重哮喘发作风险,可适度改善哮喘控制,但在生活质量和死亡率无显著改善

哮喘新药:再生元的Dupixent能够迅速改善儿童的肺功能

VOYAGE试验评估了Dupixent联合标准护理(SoC)在408例中度至重度哮喘不受控制的患儿中的安全性和有效性。